

ASPIRE

SHARING BEST PRACTICE AND
ENRICHING EXCELLENCE



Reference list for ASPIRE Interactive Clinical Tutorial held on 20 November 2023

1. Agustí A, et al. Treatable traits in the NOVELTY study. *Respirology*. 2022;27(11):929-940. [\[PMID: 35861464\]](#)
2. Almqvist L, et al. Remission of adult-onset asthma is rare: A 15-year follow-up study. *ERJ Open Res*. 2020;6(4). [\[PMID: 33263024\]](#)
3. Assaf SM and Hanania NA. Biological treatments for severe asthma. *Curr Opin Allergy Clin Immunol*. 2019;19(4):379-386. [\[PMID: 31169594\]](#)
4. Asthma Australia and National Asthma Council Australia. The Hidden Cost of Asthma. 2015. [Click to access](#). Accessed November 2023.
5. Australian Institute of Health and Welfare (AIHW), 2023. Chronic respiratory conditions: Asthma. [Click to access](#). Accessed November 2023.
6. Azim A, et al. Clinical evaluation of type 2 disease status in a real-world population of difficult to manage asthma using historic electronic healthcare records of blood eosinophil counts. *Clin Exp Allergy*. 2021;51(6):811-820. [\[PMID: 33528864\]](#)
7. Bachert C, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. *Lancet*. 2019;394(10209):1638-1650. [\[PMID: 31543428\]](#)
8. Bateman ED, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. *Am J Respir Crit Care Med*. 2004;170(8):836-44. [\[PMID: 15256389\]](#)
9. Bateman ED, et al. Positioning as-needed budesonide-formoterol for mild asthma: Effect of prestudy treatment in pooled analysis of SYGMA 1 and 2. *Ann Am Thorac Soc*. 2021;18(12):2007-2017. [\[PMID: 33979557\]](#)
10. Beasley R, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. *N Engl J Med*. 2019;380(21):2020-2030. [Click to access](#). Accessed November 2023.
11. Beeh KM, et al. Carbon footprint of severe asthma exacerbation management relative to Breezhaler dry powder inhaler. *Eur Resp J*. 2021;58(suppl 65):OA102. [Click to access](#). Accessed November 2023.
12. Bel EH, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med*. 2014;371(13):1189-97. [\[PMID: 25199060\]](#)
13. Bell J, et al. Carbon footprint of maintenance and reliever therapy (MART) versus maintenance plus SABA (Mx + SABA) regimens for asthma: Results from the healthCARE-Based environmental cost of treatment (CARBON) programme. *Eur Resp J*. 2022;60(suppl 66):4578. [Click to access](#). Accessed November 2023.
14. Bleeker ER, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting $\beta(2)$ -agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial. *Lancet*. 2016;388(10056):2115-2127. [\[PMID: 27609408\]](#)
15. Buhl R, et al. Effective management of severe asthma with biologic medications in adult patients: A literature review and international expert opinion. *J Allergy Clin Immunol Pract*. 2022;10(2):422-432. [\[PMID: 34763123\]](#)
16. Canonica GW, et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. *Allergy*. 2022;77(1):150-161. [\[PMID: 33978983\]](#)
17. Carpaij OA, et al. Childhood factors associated with complete and clinical asthma remission at 25 and 49 years. *Eur Respir J*. 2017;49(6). [\[PMID: 28596433\]](#)
18. Castro M, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. *N Engl J Med*. 2018;378(26):2486-2496. [\[PMID: 29782217\]](#)
19. Cazzoletti L, et al. The course of asthma in young adults: A population-based nine-year follow-up on asthma remission and control. *PLoS One*. 2014;9(1):e86956. [\[PMID: 24489813\]](#)
20. Çelebi Sözüner Z, Özdel Öztürk B, Aydın Ö, Mungan D, Bavbek S. The profile of severe asthmatics: Results from a specialized asthma clinic. *Tuberk Toraks* 2023;71(2):156-165. [Click to access](#). Accessed November 2023.
21. Centre of Excellence in Severe Asthma. [Click to access](#). Accessed November 2023.
22. Chapman KR, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. *Allergy*. 2019;74(9):1716-1726. [\[PMID: 31049972\]](#)
23. Commonwealth of Australia. National Asthma Strategy 2018. Canberra: Commonwealth of Australia, 2018. [Click to access](#). Accessed November 2023
24. de Marco R, et al. Prognostic factors of asthma severity: A 9-year international prospective cohort study. *J Allergy Clin Immunol*. 2006;117(6):1249-56. [\[PMID: 16750983\]](#)
25. Dejaco C, et al. Definition of remission and relapse in polymyalgia rheumatica: Data from a literature search compared with a delphi-based expert consensus. *Ann Rheum Dis*. 2011;70(3):447-53. [\[PMID: 21097803\]](#)
26. Eger K, et al. Long-term therapy response to anti-IL-5 biologics in severe asthma—a real-life evaluation. *J Allergy Clin Immunol Pract*. 2021;9(3):1194-1200. [\[PMID: 33069885\]](#)
27. Farne HA, et al. Anti-IL-5 therapies for asthma. *Cochrane Database Syst Rev*. 2017;9(9):Cd010834. [\[PMID: 28933516\]](#)
28. Farr RS. Coping styles in asthma. *J Allergy Clin Immunol*. 1999;103(1 Pt 1):29-35. [\[PMID: 9893181\]](#)
29. Foster JM, et al. "I have lost in every facet of my life": The hidden burden of severe asthma. *Eur Resp J*. 2017;50(3):1700765. [\[PMID: 28931662\]](#)
30. Garcia G, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. *Chest*. 2013;144(2):411-419. [\[PMID: 23579324\]](#)
31. Gibson PG and Powell H. Written action plans for asthma: An evidence-based review of the key components. *Thorax*. 2004;59(2):94-9. [\[PMID: 14760143\]](#)
32. Gibson PG, et al. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high

- prevalence of comorbidities: The Australian Xolair registry. *Int Med J.* 2016;46(9):1054-1062. [\[PMID: 27350385\]](#)
33. Gibson PG. Spirometry, you have an image problem! *Respirology.* 2023;28(6):577-577. [\[PMID: 37041009\]](#)
 34. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, 2023. [Click to access](#). Accessed November 2023.
 35. Hanania NA, et al. Exploring the effects of omalizumab in allergic asthma: An analysis of biomarkers in the extra study. *Am J Respir Crit Care Med.* 2013;187(8):804-11. [\[PMID: 23471469\]](#)
 36. Hanania NA, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: A randomized trial. *Ann Intern Med.* 2011;154(9):573-82. [\[PMID: 21536936\]](#)
 37. Harvey DJR and Gardiner D. 'MORAL balance' decision-making in critical care. *BJA Educ.* 2019;19(3):68-73. [\[PMID: 33456873\]](#)
 38. Hatter L, et al. ICS-formoterol reliever versus ICS and short-acting $\beta(2)$ -agonist reliever in asthma: A systematic review and meta-analysis. *ERJ Open Res.* 2021;7(1). [\[PMID: 33532465\]](#)
 39. Holm M, et al. Remission of asthma: A prospective longitudinal study from Northern Europe (RHINE study). *Eur Respir J.* 2007;30(1):62-5. [\[PMID: 17360725\]](#)
 40. Humbert M, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 Step 4 treatment): Innovate. *Allergy.* 2005;60(3):309-16. [\[PMID: 15679715\]](#)
 41. Jenkins CR, et al. Sleepwalking towards more harm from asthma. *Med J Aust.* 2023;219(2):49-52. [\[PMID: 37308167\]](#)
 42. Jin HJ. Biological treatments for severe asthma. *Yeungnam Univ J Med.* 2020;37(4):262-268. [\[PMID: 32911591\]](#)
 43. Kelada L, et al. Child and caregiver experiences and perceptions of asthma self-management. *NPJ Prim Care Respir Med.* 2021;31(1):42. [\[PMID: 34504105\]](#)
 44. Korn S, et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. *J Allergy Clin Immunol Pract.* 2021;9(12):4381-4392.e4. [Click to access](#). Accessed November 2023.
 45. Kraft M, et al. Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma. *Eur Respir J.* 2021;58(6). [\[PMID: 34112734\]](#)
 46. Menzies-Gow A, et al. An expert consensus framework for asthma remission as a treatment goal. *J Allergy Clin Immunol.* 2020;145(3):757-765. [\[PMID: 31866436\]](#)
 47. Menzies-Gow A, et al. Clinical remission in severe asthma: A pooled post hoc analysis of the patient journey with benralizumab. *Adv Ther.* 2022;39(5):2065-2084. [\[PMID: 35287231\]](#)
 48. Moffat M, et al. Sub-optimal patient and physician communication in primary care consultations: Its relation to severe and difficult asthma. *Prim Care Respir J.* 2006;15(3):159-65. [\[PMID: 16757396\]](#)
 49. Mümmler C, et al. Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy. *J Allergy Clin Immunol Pract.* 2021;9(3):1177-1185.e4. [Click to access](#). Accessed November 2023.
 50. Nair P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. *N Engl J Med.* 2017;376(25):2448-2458. [\[PMID: 28530840\]](#)
 51. O'Byrne PM, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: The optima randomized trial. *Am J Respir Crit Care Med.* 2001;164(8 Pt 1):1392-7. [\[PMID: 11704584\]](#)
 52. Ortega HG, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med.* 2014;371(13):1198-207. [\[PMID: 25199059\]](#)
 53. Ortega HG, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: A secondary analysis of the DREAM and MENSA studies. *Lancet Respir Med.* 2016;4(7):549-556. [\[PMID: 27177493\]](#)
 54. Panettieri RA, Jr., et al. Biologic use and outcomes among adults with severe asthma treated by us subspecialists. *Ann Allergy Asthma Immunol.* 2022;129(4):467-474.e3. [\[PMID: 35728746\]](#)
 55. Pavord ID, et al. Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose. *Allergy.* 2023;78(11):2921-32. [\[PMID: 37431558\]](#)
 56. Pavord I, et al. Dupilumab treatment leads to clinical asthma remission in patients with uncontrolled moderate-to-severe asthma with type 2 inflammation. *J Allergy Clin Immunol.* 2021;147(2):AB4. [Click to access](#). Accessed November 2023.
 57. Pavord ID, et al. After asthma: Redefining airways diseases. *Lancet.* 2018;391(10118):350-400. [\[PMID: 28911920\]](#)
 58. Pesce G, et al. Seventy years of asthma in Italy: Age, period and cohort effects on incidence and remission of self-reported asthma from 1940 to 2010. *PLoS One.* 2015;10(10):e0138570. [\[PMID: 26439263\]](#)
 59. Price D. Ending the reign of short-acting $\beta 2$ -agonists in Australia? (2023), Abstracts. *Respirology*, 28: 3-413. [Click to access](#). Accessed November 2023.
 60. Rabe KF, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. *N Engl J Med.* 2018;378(26):2475-2485. [\[PMID: 29782224\]](#)
 61. Radner H, et al. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. *Arthritis Res Ther.* 2014;16(1):R56. [\[PMID: 24555808\]](#)
 62. Reddel H. Asthma outcomes in Australia—Changes from 2012 to 2021. (2023), Abstracts. *Respirology*, 28: 3-413. [Click to access](#). Accessed November 2023.
 63. Reddel HK, et al. Asthma control in Australia: A cross-sectional web-based survey in a nationally representative population. *Med J Aust.* 2015;202(9):492-7. [\[PMID: 25971575\]](#)
 64. Reddel HK, et al. Risks associated with managing asthma without a preventer: Urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. *BMJ Open.* 2017;7(9):e016688. [\[PMID: 28947448\]](#)
 65. Rönmark E, et al. Outcome and severity of adult onset asthma--report from the obstructive lung disease in northern Sweden studies (Olin). *Respir Med.* 2007;101(11):2370-7. [\[PMID: 17689949\]](#)
 66. Ronmark E, et al. Remission of asthma in the middle aged and elderly: Report from the obstructive lung disease in Northern Sweden study. *Thorax.* 1999;54(7):611-3. [\[PMID: 10377206\]](#)
 67. Shulhan-Kilroy J, et al. Parents' self-reported experiences and information needs related to acute pediatric asthma exacerbations: A mixed studies systematic review. *PEC Innov.* 2022;1:100006. [\[PMID: 37364026\]](#)

68. Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med*. 2016;375(24):2335-2348. [\[PMID: 27690741\]](#)
69. Suissa S and Ernst P. Inhaled corticosteroids: Impact on asthma morbidity and mortality. *J Allergy Clin Immunol*. 2001;107(6):937-44. [\[PMID: 11398069\]](#)
70. The Royal College of Emergency Medicine. Moderate and acute severe asthma. Clinical audit 2016/17 National Report Published 2017. [Click to access](#). Accessed November 2023
71. Thomas D, et al. Asthma remission: What is it and how can it be achieved? *Eur Respir J*. 2022;60(5). [\[PMID: 35361633\]](#)
72. Tupper OD, et al. Remission and changes in severity over 30 years in an adult asthma cohort. *The Journal of Allergy and Clinical Immunology: In Practice*. 2021;9(4):1595-1603.e5. [Click to access](#). Accessed November 2023.
73. Upham JW and James AL. Remission of asthma: The next therapeutic frontier? *Pharmacol Ther*. 2011;130(1):38-45. [\[PMID: 21232553\]](#)
74. van Vollenhoven R, et al. A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS). *Ann Rheum Dis*. 2017;76(3):554-561. [\[PMID: 27884822\]](#)
75. Wang E, et al. Characterization of severe asthma worldwide: Data from the international severe asthma registry. *Chest*. 2020;157(4):790-804. [\[PMID: 31785254\]](#)
76. Wark, P. Comparing treatment efficacy with mepolizumab and omalizumab in severe asthma - "Choosebetweenamab". NCT04585997. [Click to access](#). Accessed Date 2023.
77. Wechsler M, et al. Effect of dupilumab treatment on blood eosinophil levels in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), or atopic dermatitis (AD). *J Allergy Clin Immunol*. 2021;147(2):AB140. [\[PMID: 35636689\]](#)
78. Wechsler ME, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. *J Allergy Clin Immunol Pract*. 2022;10(10):2695-2709. [\[PMID: 35636689\]](#)
79. Wechsler ME, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. *N Engl J Med*. 2017;376(20):1921-1932. [\[PMID: 28514601\]](#)
80. Westerhof GA, et al. Clinical predictors of remission and persistence of adult-onset asthma. *J Allergy Clin Immunol*. 2018;141(1):104-109.e3. [Click to access](#). Accessed November 2023.
81. Wilkinson A and Woodcock A. The environmental impact of inhalers for asthma: A green challenge and a golden opportunity. *Br J Clin Pharmacol*. 2022;88(7):3016-3022. [\[PMID: 34719810\]](#)